IntriCon Corporation (NASDAQ: IIN), a designer,
developer, manufacturer and distributor of body-worn medical and
electronics devices, today announced financial results for its 2009
first quarter ended March 31, 2009.
For the first quarter, the company reported net sales of $13.3
million, versus net sales of $16.6 million for the 2008 first
quarter. IntriCon�s 2009 first-quarter net loss was $989,000, or
$0.19 per diluted share, compared with net income of $150,000, or
$0.03 per diluted share, for the year-ago period.
For the quarter, the company�s core body-worn device segment
(hearing health, professional audio communications and medical) net
loss was $807,000, or $0.15 per diluted share, versus net income of
$207,000, or $0.04 per diluted share, for the fiscal 2008 first
quarter. IntriCon recorded a non-core electronics segment net loss
of $182,000, or $0.03 per diluted share, compared to a 2008
first-quarter non-core net loss of $57,000, or $0.01 per diluted
share.
�Like most companies, we are experiencing a very challenging
selling environment in 2009,� said Mark S. Gorder, president and
chief executive officer of IntriCon. �The first quarter, which is
typically our weakest, was further impacted by various customers
cautiously working through their inventories and delaying projects
due to economic uncertainties and lower demand for their products.
This was particularly evident in our hearing-health and
professional audio communications businesses which both had net
sale declines of approximately 30 percent compared with the 2008
first quarter.
�At this point, we expect the first half of 2009 to remain soft,
with customers cautiously beginning to replenish inventory levels
and re-engaging projects during the second half of the year.
Consequently, we are conservatively managing our business by
reducing expenses and focusing intently on remaining cash flow
positive, while prudently investing in our strategic research and
development initiatives.�
Gorder said that softness seen in other parts of the business
did not impact IntriCon�s medical sales, which grew 8 percent from
the 2008 first quarter. Business with the company�s two largest
medical OEM customers remained strong, driven by demand for
critical body-monitoring devices during the first quarter.
Company wide, 2009 first-quarter gross margins were 17.8
percent, compared to 23.2 percent in the year-ago quarter. The
decline was primarily due to lower sales levels combined with a
lower-margin product mix. While medical sales carry a higher
margin, increases were not enough to offset lower volumes in other
businesses. To improve efficiency, IntriCon continues to introduce
Six Sigma lean manufacturing methods across its
business�successfully rolling it out in various medical and hearing
health product lines.
Business Update
As previously stated, IntriCon believes that the hearing-health
market is not shrinking, but customers are delaying hearing aid
purchases. The company feels that this is chiefly due to
challenging economic conditions and the overall pullback in
consumer spending. IntriCon believes that prospects in the
professional audio communications business remain solid, but that
customers are currently working through existing inventories.
Net sales for the company�s non-core electronics business
declined 25 percent from the year-earlier first quarter. IntriCon
continues to seek to mitigate the impact of this decline by
reducing the cost structure of this business.
Said Gorder, �While the first quarter proved to be challenging,
we remain cautiously optimistic for customers to ramp up projects
in all of our core businesses during the second half of the year.
Moreover, we are pleased with the gains in our medical
business�which has been a key growth initiative for us in the
body-worn device arena.�
Milestones
Said Gorder, �Despite short-term economic conditions, R&D
remains a priority for IntriCon. We will continue to prudently
invest in initiatives that we believe will fuel long-term growth.
We remain steadfast in our goal of developing smaller, more
advanced devices that enable future applications in our core
markets.�
Several technical milestones were achieved in the first quarter
of 2009:
- IntriCon delivered a custom
high-performance digital signal processing (DSP) amplifier for a
large customer using technologies and resources available through
its strategic alliance with Dynamic Hearing;
- The company received FCC
approval for certain nanoLink applications in the United States �
these supplement the regulatory approval already received for use
in 13 European countries; and
- IntriCon delivered products
using nanoLink in certain security applications where FCC approval
is not required.
In the bio-telemetry arena, IntriCon remains active with
strategic partner Advanced Medical Electronics (AME). The company
continues to work to develop devices that wirelessly transmit
critical diagnostic and therapeutic information. In collaboration
with AME, IntriCon has received approvals for grant funding for
eight development programs and is in the process of applying for
several more.
Growth Goals
Said Gorder, �Our goals for 2009 remain firm: to develop new
bio-telemetry medical applications; gain additional traction and
market share in hearing health; and further advance our
professional audio communications product offering. We anticipate
challenging economic conditions will persist, especially during the
first half of the year. However, we are positioning ourselves for
success in body-worn devices and we are committed to developing new
products to drive long-term growth.�
Conference Call Today
As previously announced, the company will hold an investment
community conference call today, Thursday, April 23, 2009,
beginning at 4:00 p.m. CDT. Mark Gorder, president and chief
executive officer, and Scott Longval, chief financial officer, will
review first quarter performance and discuss the company�s growth
strategies. To join the conference call, dial #: 1-800-240-4186
(international 1-303-262-2138). A replay of the conference call
will be available one hour after the call ends through 11:59 p.m.
CT on Thursday, April 30, 2009. To access the replay, dial
1-800-405-2236 (international 1-303-590-3000) and enter passcode:
11130389#.
About IntriCon Corporation
Headquartered in Arden Hills, Minn., IntriCon Corporation
designs, develops and manufactures miniature and micro-miniature
body-worn medical and electronics products. The company is focused
on three key markets: medical, hearing health, and professional
audio and communications. IntriCon has facilities in the United
States, Asia and Europe. The company�s common stock trades under
the symbol �IIN� on the NASDAQ Stock Market. For more information
about IntriCon, visit www.intricon.com.
Forward-Looking Statements
Statements made in this release and in IntriCon�s other public
filings and releases that are not historical facts or that include
forward-looking terminology such as �may�, �will�, �believe�,
�expect�, �should�, �optimistic� or �continue� or the negative
thereof or other variations thereon are �forward-looking
statements� within the meaning of the Securities Exchange Act of
1934, as amended. These forward-looking statements include, without
limitation, statements concerning prospects in the miniature
body-worn device arena, new products, strategic alliances, future
growth and expansion, market fundamentals, future financial
condition and performance, prospects and the positioning of
IntriCon to compete in chosen markets and the Company�s planned
investments in research and development. These forward-looking
statements may be affected by known and unknown risks,
uncertainties and other factors that are beyond IntriCon�s control,
and may cause IntriCon�s actual results, performance or
achievements to differ materially from the results, performance and
achievements expressed or implied in the forward-looking
statements. These risks, uncertainties and factors include, without
limitation, risks related to the current economic crisis, the risk
that IntriCon may not be able to achieve its long-term strategy,
weakening demand for products of the company due to general
economic conditions, risks related to the company�s strategic
alliances and joint venture, possible non-performance of developing
the nanoLink product group and other technological products, the
volume and timing of orders received by the company, changes in the
mix of products sold, competitive pricing pressures, the cost and
availability of electronic components and commodities for the
company�s products, ability to create and market products in a
timely manner, competition by competitors with more resources than
the company, foreign currency risks arising from the company�s
foreign operations, the costs and risks associated with research
and development investments and other risks detailed from time to
time in the company�s filings with the Securities and Exchange
Commission, including the Annual Report on Form 10-K for the year
ended December 31, 2008. The company disclaims any intent or
obligation to publicly update or revise any forward-looking
statements, regardless of whether new information becomes
available, future developments occur or otherwise.
IntriCon Corporation
�
Consolidated Condensed
Statements of Operations
(Unaudited)
�
Three Months Ended March 31, 2009 �
March 31, 2008 � Sales, net $ 13,330,360 $ 16,591,380
� Costs of sales �
10,954,069 � �
12,746,689 � � Gross profit 2,376,291 3,844,691 �
Operating expenses: Selling expense 779,590 996,226 General and
administrative expense (a) 1,581,223 1,652,379 Research and
development expense �
880,530 � �
787,773
� Total operating expenses 3,241,343 3,436,378 � Operating (loss)
income (865,052 ) 408,313 � Interest expense (128,118 ) (195,625 )
Interest income 3,140 7,260 Equity in earnings of partnerships
(86,948 ) 22,156 Other income (expense), net �
53,615
� �
(5,458 ) � (Loss) income before
income taxes (1,023,363 ) 236,646 Income tax (benefit) expense �
(34,073 ) �
86,830 � � Net
(loss) income
$ (989,290 )
$ 149,816 � � Earnings per share: Basic
and diluted $ (0.19 ) $ 0.03 � Average shares outstanding: Basic
5,343,033 5,303,083 Diluted 5,343,033 5,589,894 �
(a) General and administrative expense includes $137,454 and
$128,351 of non-cash stock option expense related to FAS 123(R) for
the three-month period ended March 31, 2009 and 2008,
respectively.
IntriCon Corporation
� �
Consolidated Condensed Balance
Sheets
�
March 31,
December 31,
Assets
2009
2008
(unaudited) Current assets: � Cash $ 243,798 $ 249,396 � Restricted
cash 373,429 385,916 �
Accounts receivable, less
allowance for doubtful accounts of$284,000 at March 31, 2009 and
$389,000 at December 31, 2008
7,817,340 9,524,743 � Inventories 8,841,434 8,852,028 � Refundable
income taxes 41,083 27,645 � Note receivable from sale of
discontinued operations -- 225,000 � Other current assets �
1,258,180 �
758,193 � Total current
assets 18,575,264 20,022,921 � Machinery and equipment 38,402,125
38,016,681 Less: accumulated depreciation �
30,661,435
�
30,103,771 Net property, plant and equipment
7,740,690 7,912,910 � Goodwill 8,266,438 8,266,438 � Investment in
partnerships 1,299,826 1,386,774 � Other assets, net �
1,614,794 �
1,872,774 � Total Assets
$ 37,497,012 $
39,461,817
IntriCon Corporation
� �
Consolidated Condensed Balance
Sheets
�
March 31,
December 31,
Liabilities and Shareholders� Equity
2009
2008
(unaudited) Current liabilities: Checks written in excess of cash $
12,548 $ 95,082 Current maturities of long-term debt 1,574,110
1,503,762 Accounts payable 3,250,054 3,149,671 Income taxes payable
27,297 39,997 Deferred gain 120,478 120,478 Short term partnership
payable 260,000 260,000 Other accrued liabilities �
3,593,453 � �
4,251,707 � � Total current
liabilities 8,837,940 9,420,697 � Long term debt, less current
maturities 5,908,226 6,187,923 Other post-retirement benefit
obligations 726,353 760,608 Dynamic Hearing license agreement
payable 350,000 525,000 Long term partnership payable 760,000
760,000 Deferred income taxes 155,273 155,273 Accrued pension
liability 548,009 578,388 Deferred gain �
731,337 � �
761,456 � � Total liabilities 18,017,138 19,149,345 �
Shareholders� equity: �
Common shares, $1 par; 20,000,000
shares authorized;5,868,573 and 5,858,006 shares issued and
5,352,819 and5,342,252 outstanding at March 31, 2009 and December
31,2008, respectively
5,868,573 5,858,006 Additional paid-in capital 14,282,109
14,121,772 Retained earnings 926,044 1,915,334 Accumulated other
comprehensive loss (331,774 ) (317,562 ) Less: 515,754 common
shares held in treasury, at cost �
(1,265,078
) �
(1,265,078 ) � Total
shareholders� equity �
19,479,874 � �
20,312,472 � � Total Liabilities and Shareholders'
Equity
$ 37,497,012 �
$
39,461,817 �
Intricon (NASDAQ:IIN)
Historical Stock Chart
From May 2024 to Jun 2024
Intricon (NASDAQ:IIN)
Historical Stock Chart
From Jun 2023 to Jun 2024